Cargando…

Response to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CT

SIMPLE SUMMARY: This is the first known study to compare three FDG-PET/CT criteria (EORTC, PERCIST, imPERCIST) with CT criteria (combined modified RECIST and RECIST 1.1) used to evaluate tumor response to ICI therapy in patients with recurrent MPM as well as prediction of prognosis. All of the FDG-P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kitajima, Kazuhiro, Maruyama, Mitsunari, Yokoyama, Hiroyuki, Minami, Toshiyuki, Yokoi, Takashi, Nakamura, Akifumi, Hashimoto, Masaki, Kondo, Nobuyuki, Kuribayashi, Kozo, Kijima, Takashi, Hasegawa, Seiki, Yamakado, Koichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961728/ https://www.ncbi.nlm.nih.gov/pubmed/33806464 http://dx.doi.org/10.3390/cancers13051098

Ejemplares similares

Clinical utility of FDG-PET/CT for post-surgery surveillance of malignant pleural mesothelioma – Comparison with contrast-enhanced CT
por: Kitajima, Kazuhiro, et al.
Publicado: (2019)

Deep learning with deep convolutional neural network using FDG-PET/CT for malignant pleural mesothelioma diagnosis
por: Kitajima, Kazuhiro, et al.
Publicado: (2021)

Usefulness of Quantitative Bone Single-Photon Emission Computed Tomography/Computed Tomography for Evaluating the Treatment Response of Bone Metastasis in a Lung Cancer Patient
por: Kitajima, Kazuhiro, et al.
Publicado: (2021)

Fluorodeoxyglucose versus Choline Positron Emission Tomography/Computed Tomography Response Evaluation in Two Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Neoadjuvant Chemotherapy
por: Kitajima, Kazuhiro, et al.
Publicado: (2018)

Epigenetic Alterations and Biomarkers for Immune Checkpoint Inhibitors–Current Standards and Future Perspectives in Malignant Pleural Mesothelioma Treatment
por: Yoshikawa, Yoshie, et al.
Publicado: (2020)

Tumor‐associated macrophage‐derived inflammatory cytokine enhances malignant potential of malignant pleural mesothelioma
por: Horio, Daisuke, et al.
Publicado: (2020)

Incidence and Risk Factors of Chest Wall Metastasis at Biopsy Sites in Patients with Malignant Pleural Mesothelioma
por: Hashimoto, Masaki, et al.
Publicado: (2022)

Three tumor markers for improved efficacy in the management of patients with malignant pleural mesothelioma
por: Nakamura, Akifumi, et al.
Publicado: (2020)

Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study
por: Nakano, Takashi, et al.
Publicado: (2020)

Do we still need to debate the merits of pleurectomy/decortication vs. extrapleural pneumonectomy for malignant pleural mesothelioma?
por: Nakamura, Akifumi, et al.
Publicado: (2023)

Pelvic MRI, FDG-PET/CT, and Somatostatin Receptor Scintigraphy Findings of Treatment-Related Neuroendocrine-Differentiated Prostate Cancer
por: Kitajima, Kazuhiro, et al.
Publicado: (2021)

Should Lung-Sparing Surgery Be the Standard Procedure for Malignant Pleural Mesothelioma?
por: Ichiki, Yoshinobu, et al.
Publicado: (2020)

Extrapleural pneumonectomy or pleurectomy/decortication for malignant pleural mesothelioma
por: Hasegawa, Seiki
Publicado: (2014)

Computed Tomography and Spirometry Can Predict Unresectability in Malignant Pleural Mesothelioma
por: Bellini, Alice, et al.
Publicado: (2021)

Successful Treatment of Pulmonary Pleomorphic Carcinoma with Nivolumab: A Case Report
por: Fujimoto, Eriko, et al.
Publicado: (2018)

Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial)
por: Hasegawa, Seiki, et al.
Publicado: (2015)

Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
por: Hotta, Katsuyuki, et al.
Publicado: (2020)

Relationship Between Physical Function and Health Utility in Patients Undergoing Surgical Treatment for Malignant Pleural Mesothelioma
por: Tanaka, Takashi, et al.
Publicado: (2021)

JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
por: Miyamoto, Yosuke, et al.
Publicado: (2021)

Tiny Obturator Node Metastasis from Prostate Cancer Not Shown by FDG-PET/CT, CT, or MRI Detected by (11)C-Choline PET/CT
por: Kitajima, Kazuhiro, et al.
Publicado: (2018)

Intussusception caused by small intestine metastasis of malignant pleural mesothelioma: a case report
por: Hamaoka, Michinori, et al.
Publicado: (2021)

Malignant Pleural Mesothelioma with Bone Marrow Metastases
por: Ihara, Hiroaki, et al.
Publicado: (2018)

Liver regeneration after portal vein embolization: comparison between absolute ethanol and N-butyl-cyanoacrylate in an in vivo rat model
por: Maruyama, Mitsunari, et al.
Publicado: (2023)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Case: Authentic multimodal therapy and liver resection for an initially unresectable intrahepatic cholangiocarcinoma
por: Sakata, Koichiro, et al.
Publicado: (2018)

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
por: Ye, Zhuo-miao, et al.
Publicado: (2022)

Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study
por: Fujimoto, Nobukazu, et al.
Publicado: (2020)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers
por: Sorino, Claudio, et al.
Publicado: (2023)

Usefulness of new flex-rigid pleuroscopy in the diagnosis of malignant pleural mesothelioma
por: Ishii, Satoru, et al.
Publicado: (2019)

Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma
por: Yang, Liu, et al.
Publicado: (2022)

Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)

Pleural mesothelioma – case report
por: Klawiter, Anna, et al.
Publicado: (2010)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Malignant pleural mesothelioma: an update
por: Hajj, Glaucia N. M., et al.
Publicado: (2021)

Malignant pleural mesothelioma in situ
por: Ando, Kohei, et al.
Publicado: (2022)

Extrathoracic Metastases in Pleural Mesothelioma
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2023)

Pleural Mesothelioma in the Era of Immunotherapy
por: Chevallier, Mathieu, et al.
Publicado: (2023)

Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma
por: Woodard, Gavitt A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hf3vq5l8j7m38ucd1p2irq5ei0